introduction
For over a century, cardiologists have attempted numerous treatments to improve the prognosis of heart failure and to prevent the occurrence of sudden cardiac death. For example, device therapies have been developed during the past half-century. [1] External cardiac defibrillators for emergency treatment of sudden cardiac arrest due to ventricular fibrillation was introduced in the 1960s. [1] Since then, cardiac resynchronization therapy (CRT) with or without defibrillators (CRT/CRT-Ds) and implantable cardioverter defibrillators (ICDs) have been recommended as important device-based therapies to improve cardiac function as well as to prevent sudden cardiac death for patients with indications of moderate or severe heart failure. [2, 3] A series of randomized, clinical studies have demonstrated that CRT could effectively increase cardiac function, reverse ventricular remodeling, improve the quality of life, and significantly decrease the sudden cardiac death as compared with standardized medicinal therapies. [2, 3] However, there is still a big gap in the prevalence of use of CRT/ICD between Western and Asian countries. Understanding the current status of CRT/ICD implantation in China may help to advance scientific, technological, and clinical developments in device therapy against heart failure.
thE history and currEnt status of implantablE cardiovErtEr dEfibrillator implantation and indications in china
In China, the first ICD was implanted through the epicardium in 1992. The first transvenous ICD was performed in 1996. The first Chinese guidelines on ICD therapy for the prevention of sudden cardiac death was established by the Chinese Society of Pacing and Electrophysiology (CSPE) in 2002. Due to the increased medical interactions and collaborations between the outside world and China and because of improved education of electrophysiologists within China, gradually, the use of ICD has been accepted by more in-country cardiologists. A trend of increased use of ICD has been observed from 2002 to 2012. According to the national online registry data established by the Ministry of Health, only 186 cases received implantation of ICD in China, in 2005; however, the cases receiving ICD implantation has increased to 1903 in 2013, with an increase of 15.2% compared to cases in 2012. Among patients receiving an ICD in 2013, about 68% of patients received a single chamber device, and only 32% of patients received a dual-chamber device.
As for the indications of ICD implantation, a study [4] researched the ICD cases between January 2005 and December 2006, and found that 85.2% (121) of all cases received ICD according to the class recommendation for secondary prevention of sudden cardiac death, and only10.6% (15) of all cases received ICD implantation for primary prevention of sudden cardiac death. However, the importance of primary prevention of sudden cardiac death has been recognized during the past decade. The proportion of ICD implantation for primary prevention has gradually increased according to the online national registry data of China. For example, about 45% (855) of all cases received ICD implantation for primary prevention of sudden cardiac death in 2013, with a 42.7% increase as compared with that in 2012. Nevertheless, the persistent underuse of ICD was a significant problem in China. A recent study [5] showed that among the 497 patients with Class I indications, only 22.5% (112) of all cases received ICD implantation and 77.5% of patients refused ICD implantation for various reasons. After a mean of 11 ± 3 months follow-up, the mortality in patients receiving ICD implantation was only 1.8%, which was significantly decreased compared with the higher mortality of 9.4% in patients not receiving ICD implantations. Most of the deaths within the non-ICD group were due to the sudden cardiac death. In addition, within the year 2013, the ICD implantation rate within China was less than two cases per million inhabitants. Despite 10 years of hard proselytization, the number of ICD implants per million inhabitants is still significantly lower than that in Europe (158/1 million in 2010). Therefore, many patients in clinical practice have received suboptimal treatment, even though the benefit of ICD has been verified by many milestone clinical trials. Furthermore, the implantation of ICD has been recommended by numerous international organizations (?) as well as our own national guidelines for primary prevention of sudden cardiac death. In addition, the subcutaneous ICD has been introduced in China. Hua et al. [6] reported the first case of a successful implantation of subcutaneous ICD in our country in 2014. [7] summarized the data on CRT implantation from 193 hospitals and found that a total of 541 cases received CRT implantation, and only 59 cases of them received CRT-D treatment. Among all cases receiving CRT implantation, 74.12% of patients are male, and the mean age was (60 ± 12) with a wide age distribution range (20-90 years old). [7] Due to the incremental refinement of surgical techniques through accumulated clinical experience and due to major initiatives in training of electrophysiologists, CRT implantation has been accepted as an effective treatment against heart failure by more patients and cardiologists. In 2013, a total of 2198 cases received CRT implantation, and CRT-D accounted for 56%, which was only 10.9% in 2007. There are currently 50 hospitals with annual CRT implantation of at least 50 cases in China. According to a research report in 2011, [8] the mean age of the patients receiving CRT was 62.37 years old, and 71.16% of patients were male, and 0.11% of patients were receiving CRT replacement.
The first guideline on CRT implantation was published in Chinese by the CSPE in 2006. [9] With the update of international guidelines on CRT treatment, the Chinese guideline was revised accordingly in 2010 and 2013. In contrast to Western countries, the proportion of nonischemic cardiomyopathy is significantly higher than ischemic cardiomyopathy in patients receiving CRT implantation in China. Although the utilization of CRT for the treatment of heart failure increased rapidly in China, the CRT implantation rate per million inhabitants (1.6 cases per million inhabitants in 2013) still significantly lower than that in Europe and America. In addition, CRT implantation is still technically challenging and is only performed in select pacemaker implantation centers. Up to 2014, there are only 388 hospitals performing CRT implantation in China. Moreover, there are only seven hospitals with a volume of CRT implantation/year of more than 50 cases.
rEmotE monitoring of implantablE cardiovErtEr dEfibrillator and cardiac rEsynchronization thErapy in china
Both ICD implantation and CRT require regular follow-up to ascertain technical integrity and clinical outcomes. With the continuous increase in use of cardiac implantable devices, the regular follow-up in device clinics has become a big burden on the healthcare community. CRT and ICD with remote monitoring systems could provide information on device status, detected events (including intracardiac electrograms of arrhythmic events), and the therapies delivered. Furthermore, remote CRT monitoring could transmit continually interrogated physiological data, such as heart rate variability or intrathoracic impedance, which may be of value to predict patients at greater risk of hospitalization for heart failure. Therefore, remote monitoring is an important tool to improve patients care. Moreover, ICD and CRT devices with remote monitoring system are rapidly becoming the standard of care in Western countries. Remote follow-up of devices evaluating basic functions and parameters is now a routine clinical practice and has been shown to be safe and cost-effective. [10] In China, the first pacemaker with remote monitoring function was implanted in 2009. However, up to now, there are only 250 remote monitoring centers in China. Among all the ICD and CRT devices, only 14.2% of ICD and 8.6% of CRT are devices with remote monitoring system and the major part of remote monitoring devices involve pacemakers. [8] However, because the follow-up of remote monitoring devices is not reimbursed within China, no special clinical physicians are responsible for the remote follow-up, which has to be industry based. For example, Biotronik (Germany) sets up their own remote monitoring centers by employing a third party to be responsible for the review of online remote monitoring data in China. The third party provides the initial screening service and relays emergency data alerts to physicians. A recent registration study [11] enrolled 73 patients with CRT from 30 centers in China from 2009 to 2010. The analysis of data on remote monitoring over a 180-day period found a total of 100 abnormal events in 64 patients. Of all the events, 15% events were device related, and 85% events were disease related including atrial arrhythmia, ventricular arrhythmia, and lower biventricular pacing percentage. The detection of all the events by remote monitoring was 3-6 months earlier than by regular follow-up.
complications aftEr cardiac rEsynchronization thErapy and implantablE cardiovErtEr dEfibrillator implantation
Complications related to ICD or CRT include pericardial tamponade, pneumothorax or hemothorax, hematoma, device-related infection, device replacement, urgent cardiac surgery, myocardial infarction, and stroke/transient ischemic attack, as well as death. [12] In all patients receiving ICD or CRT in China, the incidence of complications related to ICD or CRT implantation remained low during the past 5 years (the annual rate of ICD or CRT complication is <0.4%and 0.7%, respectively), and the mortality related to ICD and CRT implant procedures was zero in 2014. Therefore, both the implantations of ICD and CRT have been shown to be procedurally safe as well as effective against heart failure.
currEnt implEmEntation issuEs with implantablE cardiovErtEr dEfibrillator implantations and cardiac rEsynchronization thErapy in china
There still remain several implementation problems in the implantation of ICD and CRT. First, a great gap in prevalence exists in both ICD implantation and CRT between Western countries and China. The ICD implantation rate per million inhabitants in China is significantly lower than that in Western countries, as well as lower than that in Japan and some other countries in Asian-Pacific area. Second, a large geographic variation in the occurrence of ICD implantation and CRT exists in China. For example, in 2014, 290 patients received ICD implantation in Zhejiang province, but only two patients received ICD treatment in Qinghai province. Similarly, the patients receiving CRT treatment varied from 367 in Zhejiang to 3 in Hainan province in 2014. The high volume of implantation procedures of ICD or CRT in economically developed regions can probably be attributed to the relatively well-developed medical and public health facilities within those regions. Although the most device implantations were performed at hospitals in Beijing, Shanghai, and Zhenjiang province, some second-class hospitals have been being involved in the implantation of ICD or CRT.
conclusions
The implantation of CRT and ICD has been used as a safe and effective treatment for heart failure as well a primary prophylactic intervention against sudden cardiac death. Increasing experience and comfort with the aforementioned techniques, coupled with the advancement of the Chinese economy, have led to many patients benefiting from CRT and ICD implantations. However, the current problems for CRT and ICD implantation in China include underuse and technologic gap between Western countries and China, as well as regional differences in the use of CRT/ICD. Understanding the current status of device therapy may help promote scientific, technological, and clinical developments for better therapy against heart failure in China.
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